Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 | P37268 | 8/20 | 0.51 |
| ▸ | CETP | P11597 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7653722 | 0.98 | FDFT1 (0.52) | FDFT1FFAR1FFAR4 | |
| SCHEMBL5545164 | 0.93 | FDFT1 (0.51) | FDFT1FFAR1FFAR4 | |
| SCHEMBL5540055 | 0.86 | FFAR1 (0.50) | FDFT1FFAR1FFAR4 | |
| SCHEMBL5539299 | 0.84 | FFAR1 (0.51) | FDFT1FFAR1FFAR4 | |
| SCHEMBL3028864 | 0.84 | MGLL (0.50) | MGLLFFAR1 | |
| SCHEMBL8862906 | 0.84 | MGLL (0.50) | MGLLFFAR1 | |
| SCHEMBL9026456 | 0.84 | MGLL (0.50) | MGLLFFAR1 | |
| SCHEMBL23085167 | 0.83 | PPARA (0.62) | CETP | |
| SCHEMBL10922528 | 0.83 | FDFT1 (0.54) | FDFT1FFAR1 | |
| SCHEMBL10624215 | 0.83 | PPARA (0.62) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476302-B2 | α-ketoamide derivatives useful endothelial lipase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-07-02 | — | — | US | claimed |
| US-12030970-B2 | Curable composition and stereolithographic resin composition comprising same | KURARAY CO., LTD. (JP) | 2024-07-09 | — | — | US | disclosed |
| US-11981763-B2 | Resin composition for stereolithographic modeling | KURARAY NORITAKE DENTAL INC. (JP) | 2024-05-14 | — | — | US | disclosed |
| EP-3900693-B1 | USE OF A RESIN COMPOSITION | KURARAY NORITAKE DENTAL INC (JP) | 2024-03-20 | — | — | EP | disclosed |
| US-11814454-B2 | Curable composition, and resin composition for stereolithography prepared therefrom | KURARAY CO., LTD. (JP) | 2023-11-14 | — | — | US | disclosed |
| WO-2023127934-A1 | ENERGY-RAY-CURABLE COMPOSITION FOR THREE-DIMENSIONAL SHAPING USE, DENTAL STRUCTURE, MOUTHPIECE, TEETH-STRAIGHTENING MOUTHPIECE, AND METHOD FOR PRODUCING DENTAL STRUCTURE | クラレノリタケデンタル株式会社 | 2023-07-06 | — | — | WO | disclosed |
| US-20230210728-A1 | ENERGY RAY-CURABLE COATING MATERIAL FOR THREE-DIMENSIONAL SHAPED ARTICLES, ENERGY RAY-CURABLE MATERIAL KIT FOR THREE-DIMENSIONAL SHAPING INCLUDING SAME, THREE-DIMENSIONAL SHAPED ARTICLE USING SAME, AND METHOD OF PRODUCTION THEREOF | KURARAY NORITAKE DENTAL INC. (JP) | 2023-07-06 | — | — | US | disclosed |
| WO-2023120611-A1 | CURABLE DENTAL COMPOSITION | クラレノリタケデンタル株式会社 | 2023-06-29 | — | — | WO | disclosed |
| WO-2023120610-A1 | DENTAL CURABLE COMPOSITION | クラレノリタケデンタル株式会社 | 2023-06-29 | — | — | WO | disclosed |
| US-11655324-B2 | Resin composition for optical shaping | KURARAY NORITAKE DENTAL INC. (JP) | 2023-05-23 | — | — | US | disclosed |
| CN-101172981-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-05-07 | — | — | CN | disclosed |
| CN-100366624-C | 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds | OTSUKA PHARMA CO LTD (JP) | 2008-02-06 | — | — | CN | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| CN-1149214-C | Triazolo gerivatives and chemokine inhibitors containing the same as the active ingredient | ������������ʽ���� | 2004-05-12 | — | — | CN | disclosed |
| US-6492364-B1 | Triazolo and derivatives as chemokine inhibitors | TORAY INDUSTRIES, INC. (JP) | 2002-12-10 | — | — | US | disclosed |
| EP-1067130-A1 | TRIAZOLO DERIVATIVES AND CHEMOKINE INHIBITORS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | TORAY INDUSTRIES, INC. (JP) | 2001-01-10 | — | — | EP | disclosed |
| US-5670526-A | ANTIINFLAMMATORY AGENT, IMMUNOSUPPRESSANT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814454-B2 | Curable composition, and resin composition for stereolithography prepared therefrom | WASF2, COPE, ARCN1 | FDFT1 924/4885CETP 3092/4885MGLL 2525/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | FDFT1 852/4885CETP 4769/4885MGLL 4717/4885 |
| US-12030970-B2 | Curable composition and stereolithographic resin composition comprising same | ARL1, ASH2L, VCL | FDFT1 3440/4885CETP 3271/4885MGLL 725/4885 |
| US-20230210728-A1 | ENERGY RAY-CURABLE COATING MATERIAL FOR THREE-DIMENSIONAL SHAPED ARTICLES, ENERGY RAY-CURABLE MATERIAL KIT FOR THREE-DIMENSIONAL SHAPING INCLUDING SAME, THREE-DIMENSIONAL SHAPED ARTICLE USING SAME, AND METHOD OF PRODUCTION THEREOF | KIT, SETD7, SETDB1 | FDFT1 3283/4885CETP 1037/4885MGLL 3968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.